Neos Therapeutics

Neos Therapeutics Completes $20.6 Million Financing to Further Advance its Late-Stage ADHD Product Pipeline

Dallas/Fort Worth, TX (February 25, 2015) – Neos Therapeutics, Inc. (“Neos” or “the Company”), a specialty pharmaceutical company with a late-stage pipeline of innovative extended-release (“XR”) products for Attention-Deficit Hyperactivity Disorder (“ADHD”), today announced that it has completed an oversubscribed round of financing, raising a total of $20.6 million. The financing included investments by Presidio Partners, Crabtree Partners, CAC LLC, Delaware Street Capital, Burrill Life Sciences Capital Fund III and Essex Capital Corporation, as well as other investors.

With the successful completion of this financing and the recent submission of a New Drug Application (NDA) for its methylphenidate XR-ODT drug candidate, NT-0102, an ADHD medication based on Neos’ patented XR-ODT technology, the company is well positioned for growth.

Proceeds from this financing will support the Company’s efforts during the FDA review of NT- 0102 as well as the submission of NDAs for two additional ADHD drug candidates, an amphetamine XR-ODT and an amphetamine XR-Liquid Suspension.

Stimulant medications such as methylphenidate and amphetamine are effective in ameliorating the symptoms of ADHD, and extended-release formulations of these medications allow for once-daily dosing. However, recent data suggest that a significant percentage of children are unable to easily swallow solid dosage forms, and many remain uncomfortable doing so through adolescence. Neos’ XR-ODT and XR-Liquid product candidates are designed to provide patient- friendly dosage forms for those who have difficulty swallowing or do not like to swallow intact tablets or capsules and may benefit from extended-release formulations.

“We are grateful to our investors for their continued confidence and support of the Company and our management team,” commented Vipin K. Garg, Ph.D., President and CEO of Neos. “This places the Company in an excellent financial position as we prepare to transition to a commercial enterprise during the next six to twelve months.”

About Neos Therapeutics

Neos Therapeutics, Inc. is a fully integrated specialty pharmaceutical company. The Company is initially focusing on ADHD with three proprietary products in late-stage development that provide patient-friendly dosage forms incorporating controlled and extended-release (XR) oral disintegrating tablets (ODT) and liquid suspensions. In addition, Neos manufactures and markets a generic of Tussionex® (hydrocodone and chlorpheniramine) extended-release oral suspension for the treatment of cough and upper respiratory symptoms of a cold. The Company’s products are developed and manufactured using its proprietary and patented ion resin technology. For more information, visit www.neostx.com.

This press release contains certain forward-looking statements that include projections and may also include words such as may, will, expects, believes, anticipates, plans, estimates, seeks, could, intends, and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statement.

CONTACTS:

Vipin K. Garg, Ph.D. President and CEO Neos Therapeutics (919) 434-6643 vgarg@neostx.com

Richard I. Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 reisenstadt@neostx.com

Arcadia Biosciences

ARCADIA BIOSCIENCES AND MAHYCO ACHIEVE PRODUCT DEVELOPMENT MILESTONE FOR WATER USE EFFICIENT RICE

– Technology Improves Yield Under Both Periodic and Severe Water Stress –

DAVIS, Calif. and Jalna, INDIA (February 9, 2015) – CMEA Capital portfolio company Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, and Maharashtra Hybrid Seeds Co. Ltd. (Mahyco), a major seed company in Southeast Asia, today announced the achievement of a key milestone in the development of Water Use Efficient (WUE) rice. Arcadia received a significant but undisclosed payment for this milestone.

Arcadia’s WUE technology seeks to improve crop yields under episodic water-stress conditions typical to global agriculture, as well as under severe drought conditions. WUE rice developed by Mahyco is expected to be among early examples of crops bred to withstand the varying environmental effects of climate change while expanding the range of usable acreage for crop production.

Mahyco demonstrated that Arcadia’s WUE technology significantly increased plant growth under normal and water-stress conditions in multiple rice lines developed by Mahyco. The rice lines incorporating Arcadia’s WUE technology showed double-digit increases in key plant performance and yield measures.

Rice is the world’s most valuable crop, grown on 162 million hectares globally with a harvest value of $334.7 billion in 2012 (FAO 2012 statistics; FAOSTAT). This crop plays a critical role in food security for more than half of the world’s population. Based on

current growth rates, India is expected to overtake China as the world’s most populous nation by the year 2030. The United Nations Food and Agriculture Organization (FAO) estimates that 221 million people in India, or about one-fifth of the population, are undernourished.

“At a time when farmers in India face significant pressure to increase productivity, factors such as urban growth, drought and rainfall variations are limiting water resources available for agriculture, particularly for water intensive crops such as rice,” said Eric Rey, president and CEO of Arcadia. “Through our collaboration with Mahyco on WUE and other agronomic technologies, we’re working to increase yields and improve efficiency in the use of key inputs, such as fresh water.”

About Arcadia Biosciences, Inc.

Based in Davis, Calif., with additional facilities in Seattle, Wash. and Phoenix, Ariz., Arcadia Biosciences is focused on developing agricultural products that benefit the environment and enhance human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition technologies and products are aimed at creating healthier ingredients and whole foods with lower production costs. The company was recently listed in the Global Cleantech 100, representing the most innovative and promising ideas in clean technology, and was previously named one of MIT Technology Review’s 50 Smartest Companies. For more information, visit www.arcadiabio.com.

About Mahyco

Established in 1964 by Dr. Badrinarayan R. Barwale, Mahyco is a pioneer and leader in the Indian seed industry. The company strives to provide quality seeds. Since its inception it has been engaged in plant genetic research and production of quality seeds for the farming community of India. Currently, it is engaged in the research, production, processing and marketing of approximately 115 products in 30 crop species including cereals, oilseeds, fiber and vegetables. Mahyco is also developing genetically enhanced

“With this milestone, we are closer to bringing the benefits of this technology to the farmers who are challenged with reduced water availability on their farms and improving the overall productivity of the crop,” said Usha Zehr, chief technology officer of Mahyco.

crops with the use of gene transfer technology. Mahyco has a national presence with its network across the country. For more information visit www.mahyco.com.

###

Wildcat Discovery Technologies, Inc.

Wildcat Discovery Technologies DOE Vehicle Technologies Award Generates Promising Si Anode Electrolyte Leads

Wildcat identifies new non-carbonate electrolytes that outperform carbonate solutions.

San Diego, CA – January 26, 2015 – CMEA Capital portfolio company Wildcat Discovery Technologies, a technology company using high throughput methods to develop improved battery materials, announced that it has achieved a significant milestone on its grant from the U.S. Department of Energy’s (DOE) Office of Energy Efficiency and Renewable Energy (EERE). Wildcat is an award recipient under the 2013 Vehicle Technologies Program Funding Opportunity Announcement DE-FOA-0000793.

The goal of the project is to develop novel non-carbonate based electrolytes for silicon anodes, which will enable substantial improvements in energy density and cost relative to today’s lithium-ion batteries. Wildcat has used its unique accelerated development method to prepare and evaluate over 2,500 unique electrolyte formulations. Wildcat has now identified an additive-free non-carbonate electrolyte that outperforms the carbonate baseline electrolyte by 50% when cycled in full cells with a silicon anode.

“We are extremely happy with our progress at this point in the project,” said Dr. Deidre Strand, Wildcat’s Chief Scientific Officer. “An additive-free non-carbonate electrolyte that outperforms carbonate solutions opens the door for further improvements as we move forward and explore the addition of additives.”

Wildcat has also measured gas generation for its best-performing non-carbonate electrolyte solutions using its newly launched high throughput in-situ gas sensing technology. Gas generation for Wildcat’s non-carbonate formulations are comparable to carbonate-based solutions – another promising result.

The next phase of the project, expected to conclude in December of this year, will focus on the impact of additives, high temperature improvements, and use with higher voltage cathodes above 4.2V. Argonne National Lab will evaluate Wildcat’s new electrolyte solutions in 18650 cells constructed with a silicon anode provided by 3M later this year.

Tien Q. Duong from the DOE’s Office of Vehicle Technologies, Energy Efficiency and Renewable Energy Office, added “Wildcat’s work on this project validates the power of their high throughput approach and their ability to rapidly identify promising new battery materials.”

A more detailed technical white paper is available on Wildcat’s website at: www.wildcatdiscovery.com/whitepapers.

About Wildcat Discovery Technologies
Wildcat Discovery Technologies accelerates the discovery of new materials for energy applications, with a focus on the development of advanced materials for rechargeable and primary batteries. Wildcat’s experienced team of scientists uses proprietary high-throughput tools to rapidly develop and optimize breakthrough materials, with corporate partners throughout the global battery and materials supply chains. Wildcat was also recently named one of the “50 Most Innovative Companies” by Technology Review magazine. For more information and white papers detailing more of their work, please visit www.wildcatdiscovery.com.

For more information about Wildcat:
Jon Jacobs
Wildcat Discovery Technologies
VP, Business Development
(858) 550-1980 x114
jjacobs@wildcatdiscovery.com

Neos Therapeutics

Neos Therapeutics Announces Submission of a New Drug Application for its Methylphenidate Extended Release Oral Disintegrating Tablet (XR-ODT) for the Treatment of ADHD

Dallas-Fort Worth, TX (January 12, 2015) – Neos Therapeutics, Inc. (“Neos”), a specialty pharmaceutical company with a late-stage pipeline of innovative extended release (“XR”) products for Attention-Deficit Hyperactivity Disorder (“ADHD”), announced today that it has submitted a New Drug Application (NDA) for its methylphenidate XR-ODT drug candidate, NT-0102, an ADHD medication based on its patented XR-ODT technology.

Orally disintegrating tablets (“ODTs”) differ from traditional tablets and capsules in that they are designed to quickly disintegrate on the tongue, rather than being swallowed whole. XR-ODTs provide a patient-friendly dosage form for those who have difficulty swallowing or do not like to swallow intact tablets or capsules and benefit from extended release formulations. NT-0102 is an extended release ODT formulation of methylphenidate that may be the first XR-ODT for the treatment of ADHD. The Neos XR-ODT formulation quickly disintegrates in the mouth without water, and has been shown to control ADHD symptoms through twelve hours post-dose in a pivotal clinical trial.

The pivotal clinical trial was a multicenter, randomized, double-blind, placebo-controlled laboratory classroom study in children (ages 6-12) with ADHD. NT-0102 met all primary and secondary efficacy endpoints, showing statistically significant improvement versus placebo on both the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Scale (p<0.0001) and the Permanent Product Measure of Performance (PERMP) scale (p<0.0001). The SKAMP is a validated rating scale that measures classroom manifestations of inattention, hyperactivity, and impulsivity; the PERMP is a five-page math test that provides an objective assessment of effortful performance in the classroom. No serious adverse events were reported during the study and the adverse event profile was consistent with the drug’s mechanism of action.

“The submission of the NDA for NT-0102 is a major milestone for Neos Therapeutics and we look forward to working closely with the FDA during the review period”, stated Vipin K. Garg, Ph.D., President and CEO of Neos. Dr. Garg further stated that, “Neos is poised to submit additional NDAs for its ADHD pipeline drug candidates in 2015.”

“ADHD is a condition that can result in significant academic and social impairment for patients. The burden on family members and caregivers can be enormous. The submission of NT-0102 NDA to the FDA brings us one step closer to having an easy to administer treatment option for those patients with ADHD who prefer not to swallow tablets or capsules,” noted Dr. Ann Childress (Center for Psychiatry and Behavioral Medicine, La Vegas, NV), lead investigator for the study.

About Neos Therapeutics

Neos Therapeutics, Inc. is a fully integrated specialty pharmaceutical company. The Company is initially focusing on ADHD with three proprietary products in late-stage development that provide patient-friendly dosage forms incorporating controlled and extended release oral disintegrating tablets (ODTs) and liquid suspensions. In addition, Neos manufactures and markets a generic of Tussionex® (hydrocodone and chlorpheniramine) extended-release oral suspension for the treatment of cough and upper respiratory symptoms of a cold. The Company’s products are developed and manufactured using its proprietary and patented ion resin technology. For more information, visit www.neostx.com.

This press release contains certain forward-looking statements that include projections and may also include words such as may, will, expects, believes, anticipates, plans, estimates, seeks, could, intends, and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.

 

 

 

CONTACTS:


Vipin K. Garg, Ph.D.                                                                     Richard I. Eisenstadt
President and CEO                                                                       Chief Financial Officer

Neos Therapeutics                                                                       Neos Therapeutics 
(919) 434-6643                                                                           (972) 408-1389

vgarg@neostx.com                                                                                                                   reisenstadt@neostx.com

Pamela K. Woods

Executive Assistant

NEOS Therapeutics

Velocity Pharmaceutical Development

Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus

– Statistically Significant Data from Phase 2 Study Support Safety and Efficacy of Once Daily Dosing of NK-1 Antagonist, VPD-737 (serlopitant) —

SOUTH SAN FRANCISCO, Calif.Dec. 17, 2014 /PRNewswire/ — Tigercat Pharma, Inc. today announced positive results of a Phase 2 study evaluating the investigational oral NK-1 receptor antagonist VPD-737 (serlopitant), for the treatment of patients with severe, chronic itch who are unresponsive or inadequately responsive to the current standard of care, including topical steroids and antihistamines.

The primary efficacy endpoint was percent change in Visual Analog Scale (VAS) itch score from baseline, comparing drug to placebo for each dose group. Statistically significant reduction in VAS scores were seen in both the 1mg and 5mg dose groups. The response was durable over the entire treatment period.  VPD-737 is safe and well tolerated.

Gil Yosipovitch, M.D, Professor Chair of Dermatology and Director of the Temple Itch Center at Temple University School of Medicine, a principal investigator for the Phase 2 study remarked: “Today is an important day for patients who suffer from severe, chronic pruritus.   The results of this study give tremendous hope for the millions of patients who suffer from this debilitating condition, which erodes their quality of life.  I look forward to the further development of VPD-737 and hopefully adding it to the treatment armamentarium for patients suffering from intractable pruritus.”

Edward Schnipper, M.D., a Founder and Chief Medical Officer at Tigercat Pharma, Inc. remarked: “We are very pleased with the conduct and outcome of this study. We are continuing development of this drug for patients who desperately need a treatment regimen more efficacious than the current standard of care.”

About the Phase 2 Study
The Phase 2 study was a randomized, double-blind, parallel group, placebo-controlled, dose-finding and efficacy study of VPD-737 (serlopitant) for the treatment of patients with chronic pruritus.

The study enrolled 257 patients from 25 sites in the United States with VAS of 7 or greater at baseline (on a scale of 1 to 10). Patients were males and females between 18 and 65 years with confirmed chronic pruritus for a period lasting more than six weeks. Patients were unresponsive or inadequately responsive to topical steroids or antihistamines.

The patients were randomized into four equal groups of the following doses: 0.25, 1, 5 mg and placebo tablets administered daily for 6 weeks. The primary efficacy endpoint was the percent change in VAS from baseline, comparing drug to placebo for each dose group. The primary analysis was conducted on an Intent-to-Treat (ITT) population.

Tigercat utilized the services of TKL Research, Inc., a contract research organization, to conduct the trial.

ABOUT TIGERCAT PHARMA, INC.
Tigercat Pharma, Inc., is a clinical stage biopharmaceutical company focused on the development and commercialization of VPD 737(serlopitant), an NK-1 receptor antagonist, currently in late stage clinical development for the treatment of chronic pruritus. Tigercat investors included Velocity Pharmaceutical Holdings, LLC, and Remeditex Ventures, LLC.  More information is available at www.tigercatpharma.com.

ABOUT VELOCITY PHARMACEUTICAL DEVELOPMENT, LLC
Velocity Pharmaceutical Development (VPD) is a pharmaceutical development organization dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model. VPD seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. VPD then manages a development program for each drug candidate intended to generate convincing human proof of concept data (generally by conducting a phase 2 clinical trial). Following successful human proof of concept, VPD then seeks a large pharmaceutical company acquirer for each program. VPD is staffed by a seasoned team of clinical drug developers with expertise identifying attractive drug candidates, target markets, and designing and managing outsourced clinical trials. This expert team manages multiple single asset companies to remove the costly overhead and misaligned incentives present in traditional biotechnology company structures. VPD believes this new capital-efficient model will yield attractive new drugs to treat patients with significant unmet clinical needs. The company is located in South San Francisco, California. More information is available at www.vpd.net.

ABOUT VELOCITY PHARMACEUTICAL HOLDINGS, LLC
Velocity Pharmaceutical Holdings, LLC, is an entity funded by CMEA Capital that makes investments in highly virtual, project-focused pharmaceutical development companies that are managed by Velocity Pharmaceutical Development, LLC. More information is available at www.vpd.net and www.cmea.com.

ABOUT REMEDITEX VENTURES, LLC
Remeditex seeks to develop opportunities in need of commercial validation, guidance, and capital. Its mission is to develop early stage biomedical science and make Texas and Colorado a preferred location for biotechnology companies, venture capitalists, and entrepreneurs by accelerating the pace of commercialization of biomedical research; help create and support a thriving biotechnology industry; attract biotech venture capital to Texas and Colorado; and achieve significant returns to support the next generation of promising science. More information is available at www.remeditex.com.

General inquires:

Leslie Loven
Velocity Pharmaceutical Development
1-415-524-7326
leslie@vpd.net

Media inquiries:

Hunter Marshall
MacDougall Biomedical Communications
Main: 1-650-339-7533
Direct: 1-510-693-2792
hmarshall@macbiocom.com

 

SOURCE Velocity Pharmaceutical Development

RELATED LINKS
http://www.vpd.net

Neos Therapeutics

Neos Therapeutics Announces Issuance of Key Patent Covering its Extended Release Oral Disintegrating Tablet (XR-ODT) Platform Technology

Dallas-Fort Worth, TX (October 8, 2014) – Neos Therapeutics, Inc. (“Neos”), a specialty pharmaceutical company with a portfolio of novel and proprietary oral drug delivery technologies as well as a late-stage pipeline of innovative extended release (“XR”) products for Attention Deficit Hyperactivity Disorder (“ADHD”), announced today that is has been granted a key patent (US Patent No. 8,840,924) covering its XR-oral disintegrating tablet (“ODT”) technology, known as Rapidly Disintegrating Ionic Masking™ (RDIM™).

RDIM™ utilizes an orally disintegrating, controlled release, taste-masked pharmaceutical composition that can withstand compression forces associated with standard tableting technology, allowing for a drug to be incorporated into the ODT dosage form using ion resin technology. This technology not only provides extended release or controlled release properties, it can also mask the unpleasant taste of the drugs.

ODTs are tablets that disintegrate quickly when placed on the tongue and thus facilitate ingestion of a tablet. By combining the ODT dosage form with controlled release properties, Neos’ XR-ODT formulations can benefit those patients who have difficulty swallowing intact tablets and capsules and who require extended release products. XR-ODTs are easily transported, can be taken without liquid and provide convenient and easy to administer dosage form for patients and caregivers.

“This XR-ODT technology is embedded in two near-term products that Neos is developing. NT-0102 is an XR-ODT of Methylphenidate and NT-0202 is an XR-ODT of Amphetamine. Methylphenidate and Amphetamine are two of the most prescribed compounds for the treatment of ADHD. The application of XR-ODT technology to ADHD was obvious as the medications for ADHD need to be administered effectively and last all day long,” stated Vipin K. Garg, Ph.D., President and CEO of Neos.

“This patent further strengthens Neos’ intellectual property position and further protects our proprietary product candidates,” said Mark Tengler, Chief Technology Officer of Neos. “We believe that our XR-ODT technology will have a broad applicability in multiple therapeutic areas.”

 

About Neos Therapeutics

Neos Therapeutics, Inc. is a fully integrated specialty pharmaceutical company. The Company is initially focusing on ADHD with three proprietary products in late-stage development that provide patient-friendly dosage forms incorporating controlled and extended release oral disintegrating tablets (ODT) and liquid suspensions. In addition, Neos manufactures and markets a Generic of Tussionex®, for the treatment of cough and cold. The Company’s products are developed and manufactured using its proprietary and patented ion resin technology. For more information, visit www.neostx.com.

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

 

 

 

This press release contains certain forward-looking statements that include projections and may also include words such as may, will, expects, believes, anticipates, plans, estimates, seeks, could, intends, and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.

 

 

CONTACTS:

 

Vipin K. Garg, Ph.D.                                                                                    Richard I. Eisenstadt

President and CEO                                                                                       Chief Financial Officer

Neos Therapeutics                                                                                         Neos Therapeutics

(919) 434-6643                                                                                               (972) 408-1389

vgarg@neostx.com

Jobvite

Jobvite Secures $25 Million Of Expansion Capital Led By Catalyst Investors

San Mateo, Calif. — (October 7, 2014) — CMEA Capital portfolio company Jobvite, the comprehensive recruiting solution for the world’s fastest growing companies, today announced that it closed $25 million in Series D funding led by growth equity firm Catalyst Investors. Catalyst joins existing investors CMEA, ATA Ventures and Trident Capital. The investment serves as a strong endorsement of Jobvite’s vision to create a new standard in recruiting for the modern business.

Jobvite is the only standalone recruiting solution that offers the necessary tools to engage and hire candidates by taking advantage of social, mobile, video and data analytics. The company currently fuels the growth of more than 1,600 companies including Starbucks, Twitter and Farmers Insurance, as well as nine of the last 11 top tech IPOs. Today, recruiters take a multi-channel approach to nurturing and engaging prospective candidates at every touch point. Jobvite is transforming recruiting from the era of job boards and legacy software to a new phase in which recruiting is now marketing.

“We see Jobvite as transformative and innovative, serving fast-growing companies and enterprises alike in recruiting the best employees,” said Ryan McNally, partner and co-founder of Catalyst Investors. “We are confident that with additional capital and resources, Jobvite will continue to lead the industry in providing best-of-breed recruiting solutions.”

“Today, a company’s success or failure sits on the shoulders of its talent,” said Dan Finnigan, CEO of Jobvite. “Recruiting is critical to moving industries forward and spurring innovation. Catalyst is a key partner who understands that legacy systems can no longer support the modern workforce and aligns with our mission to deliver the platform to meet the demands of modern recruiting. This round of financing validates our vision and will enable us to bring this vision to life on a global scale.”

Jobvite has experienced strong growth since its first funding round in 2007 and continues to deliver impressive levels of innovation. Major milestones include:

  • Rapid Innovation — Jobvite provides recruiters with innovations to harness the most significant technological advancements and trends including social, mobile, big data and beyond.  The company’s comprehensive recruiting solution supports recruiters throughout the entire recruiting “funnel” with Jobvite Refer, Jobvite Engage, Jobvite Hire,Jobvite Video and Jobvite’s mobile career website solution.
  • A Recruitment Standard  — Jobvite empowers recruiters to move beyond legacy applicant tracking systems to focus on building talent pools and engaging candidates at each step in the recruiting process. The company helps recruiters to source candidates, nurture relationships and hire talent by utilizing all available channels.
  • Expanded Customer Base — Jobvite powers the expansion of fast-growth companies like TED Conferences to enterprises like GroupM and SM Energy. Jobvite customers have hired more than 200,000 people; 46 million job seekers interact with a Jobvite-powered career site annually. Since Jobvite’s last investment, the company has increased the number of job seeker profiles in its system by 400 percent amounting to 33 million profiles. Additionally, the number of hires through Jobvite has increased by 566 percent.
  • Continued Employee Growth — Jobvite has experienced significant employee growth since its inception in 2003. The company has more than doubled its employee count since its last investment, reaching more than 100 employees.


Contact:
Kristen Ford or Laura Spaventa
415-625-8555
jobvite@launchsquad.com


About Jobvite

Jobvite is the leading recruiting platform for the social web. Today’s fastest-growing companies use applicant tracking,recruiter CRM and social recruiting software solutions from Jobvite to target the right talent and build the best teams. Jobvite is a complete, modular Software-as-a-Service (SaaS) platform which can optimize the speed, cost-effectiveness and ease of recruiting for any company. For more information, visit www.jobvite.com.

 

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

Arcadia Biosciences

ARCADIA BIOSCIENCES AND ARBORGEN TO DEVELOP DROUGHT-TOLERANT AND NITROGEN-EFFICIENT EUCALYPTUS TREES

– Improved Varieties Will Enhance Productivity and Sustainability of Purpose-grown Forests –

DAVIS, Calif. (October 7, 2014) –  CMEA Capital portfolio company Arcadia Biosciences, Inc., an agricultural biotechnology company, and ArborGen announced an agreement to incorporate Arcadia’s water use efficiency (WUE) and nitrogen use efficiency (NUE) technologies in eucalyptus trees.

The license agreement will allow ArborGen, a global supplier of seedling products and elite genetics to the forest industry, to develop eucalyptus trees that produce higher yields per unit of nitrogen and water. The license also includes the use of the technologies in poplar trees and an option for use in pine trees.

Three in ten of the world’s forests are used for production of wood and non-wood forest products, according to the Food & Agriculture Organization of the United Nations, and the global acreage of purpose-grown forests is increasing. In 2000, managed forest plantations provided an estimated 35 percent of global roundwood supply. By 2020, that number is expected to increase to 44 percent.

However, climate change is threatening forest productivity. Shifting rainfall patterns and drought have a direct impact on tree health. Longer dry seasons and multi-year droughts sensitize forests to other stresses, including pests, disease and fire.

“Our WUE and NUE technologies enable plants to use water and nitrogen more efficiently, producing high yields under environmental stress,” said Eric Rey, president and CEO of Arcadia. “Increasing the productivity of purpose-grown forests will help relieve the strain on limited land and water resources to meet the growing global demand for wood products.”

“ArborGen consistently works to develop and use the best technologies to improve the health and productivity of trees. Our partnership with Arcadia will allow us to continue to do just that,” stated Andrew Baum, president and CEO of ArborGen.

About Arcadia Biosciences

Based in Davis, Calif., with additional facilities in Seattle, Wash. and Phoenix, Ariz., Arcadia Biosciences is focused on developing agricultural products that benefit the environment and enhance human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salt Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition technologies and products create healthier ingredients and whole foods with lower production costs. The company was recently named one of MIT Technology Review’s 50 Smartest Companies and was previously recognized by AlwaysON as one of the GoingGreen Silicon Valley Global 200. For more information, visit www.arcadiabio.com.

About ArborGen

ArborGen is a global supplier of seedling products and elite genetics to the forest industry. Through innovations in conventional breeding, improved genetics and emerging biotechnology advances, ArborGen is developing high-value products that significantly improve the productivity of a given acre of land. These products enable ArborGen’s customers to grow trees that yield more wood per acre with greater consistency and quality in a shorter period of time. ArborGen’s work is improving the sustainability of working forests while helping to meet the world’s growing need for wood, fiber and energy. For more information, visit www.arborgen.com.

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

 

###

Neos Therapeutics

Neos Therapeutics Acquires all Commercialization and Profit Rights to Generic Tussionex® (Extended Release Hydrocodone Polistirex/Chlorpheniramine Polistirex) from Chiesi USA and Coating Place, Inc.

Dallas-Fort Worth, TX, Cary, NC and Verona, WI (September 8, 2014) – CMEA Capital portfolio company Neos Therapeutics, Inc. (“Neos”), a specialty pharmaceutical company with a portfolio of novel and proprietary oral drug delivery technologies as well as a late-stage pipeline of innovative extended release (“XR”) products for Attention Deficit Hyperactivity Disorder (“ADHD”), announced today the completion of the acquisition of all of the commercialization and profit rights to its Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended Release Suspension Product from its collaboration partners Chiesi USA, Inc., and Coating Place, Inc.

The antitussive/antihistamine combination product is a generic equivalent of the product currently sold under the Tussionex® brand name. The product is indicated for the relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children six years of age and older. According to Symphony Health Solutions, a third-party provider of prescription data, there were approximately 2.5 million total prescriptions of Tussionex® and related generic products in 2013.

“We are pleased to acquire the full rights to this product as we believe that there is a significant opportunity to expand our sales given the demand within the market. Antitussives are among the most commonly prescribed medications for the treatment of coughs and colds,” said Dr. Vipin K. Garg, President and CEO of Neos. “Establishing a commercial presence is a natural progression for Neos as its late-stage ADHD pipeline moves forward in the approval process,” he added.

“This transaction is in alignment with our strategy to focus our growth of the company in the hospital and related specialty markets,” said Ken McBean, President of Chiesi USA. “We are pleased that Neos, our manufacturing partner for the product, will now have the opportunity to also market this product.”

“We are committed to continuing our relationship with Neos as its exclusive supplier of the drug resin complexes used in the suspension” added Tim Breunig, CEO of Coating Place, Inc.”

About Neos Therapeutics

Neos Therapeutics, Inc. is a fully integrated specialty pharmaceutical company. The Company is initially focusing on ADHD with three proprietary products in late-stage development that provide patient-friendly dosage forms incorporating controlled and extended release oral disintegrating tablets (ODT) and liquid suspensions. In addition, Neos manufactures and markets a Generic of Tussionex®, for the treatment of cough and cold. The Company’s products are developed and manufactured using its proprietary and patented ion resin technology. For more information, visit www.neostx.com.

About Chiesi USA, Inc.

Chiesi USA, Inc., headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company’s strategy are to focus its commercial and development efforts in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within the Company’s focus areas; and generate revenues by marketing approved generic products through the Company’s wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. For more information, visit www.chiesiusa.com.

About Chiesi Farmaceutici S.p.A.

Chiesi Farmaceutici is a research-focused international group, with more than 75 years of experience headquartered in Parma (Italy). Chiesi researches, develops and commercializes innovative pharmaceutical solutions in the respiratory therapeutics and specialist medicine areas. In 2013, Chiesi achieved sales of over 1.2 billion Euros, constituting double digit growth over 2012. Its R&D centers in Parma (Italy), Paris (France), Rockville (USA), Chippenham (UK) and the R&D team of the newly-acquired Danish company Zymenex, integrate their efforts to advance Chiesi’s pre-clinical, clinical and registration programs. The Chiesi Group employs approximately 3900 people, 480 of whom are dedicated to R&D activities. For more information, please visit www.chiesi.com.

About Coating Place, Inc.

Coating Place is an innovative pharmaceutical company specializing in Wurster fluid bed technology focused on drug delivery system development and contract manufacturing.  We provide our customers with modified & extended release bulk active products through cutting-edge development, unique manufacturing capabilities and integrated quality philosophy.  CPI’s extended release drug-resin API’s are developed using our patented DRC Technology combined with our trade secret linear scale-able Wurster manufacturing process. For more information, please visit www.coatingplace.com.

Tussionex® is a registered trademark of the UCB Group of companies.

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

Foro Energy

Petrobras and Foro Energy Announce Signing of Technology Cooperation Agreement

HOUSTON–(BUSINESS WIRE) – August 26th, 2014 Petrobras and Foro Energy today announced the signing of a Technology Cooperation Agreement (TCA) for high power laser drilling research and development. The program with the Leopoldo Americo Miguez de Mello Research & Development Center (CENPES) will focus on developing a next generation high power laser drilling system. The TCA sets the framework for collaborative research between Petrobras and Foro Energy over an initial three-year time period with the opportunity for extensions.

The ultimate goal of the collaboration will be to achieve a step change in drilling performance in the challenging pre-salt (subsalt) reservoir. High power lasers have the potential to deliver step change performance in drilling by increased rate of penetration, extremely low weight on bit and torque, thereby prolonging bit life and lower drilling cost per foot.

The Technology Cooperation Agreement was signed by Andre Cordeiro Executive Manager of CENPES and Paul Deutch, CEO of Foro Energy. It follows a previously signed Memorandum of Understanding (MoU) between the two companies enabling the opportunity for wider collaboration in utilizing high power lasers for additional applications.

Petroleo Brasileiro S.A. — Petrobras (NYSE:PBRwww.Petrobras.com.

Foro Energy www.ForoEnergy.com. Foro Energy is commercializing high-power lasers for the oil, natural gas, geothermal and mining industries. Their hardware platform transmits high-power lasers over long distance using fiber optic cables to more efficiently drill, complete and work over wells.

Contact:
Foro Energy
Paul Deutch, 713-456-3350

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.